Janssen Research & Development was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s ...

JPMorgan lowered the firm’s price target on Moderna (MRNA) to $45 from $59 and keeps an Underweight rating on the shares. The firm updated ...

The presumptive new CDC director, Dave Weldon, is a known vaccine safety skeptic. In contrast, the FDA choice — Johns Hopkins ...

Trump’s picks, made late Friday, did little to dispel the notion that the nation’s federal health agencies are facing a major ...

Marty Makary, an outspoken critic of the nation’s food and drug regulator, stands to shake up the FDA’s standards in science ...

Makary and Weldon, who have criticized the agencies they may soon run, were joined by Janette Nesheiwat, Trump’s pick to be ...

We recently compiled a list of the 10 Most Promising Cancer Stocks According to Hedge Funds. In this article, we are going to ...

President-elect Donald Trump has nominated a critic of COVID-19 health measures to lead the Food and Drug Administration.

Moderna, Inc.'s stock plummets as challenges mount, including vaccine skepticism, competitive pressures, and the RFK ...

As the biopharma industry braces for a second term under President-elect Donald Trump, speculation is swirling around the ...

According to the CRL, the FDA is continuing to assess the safety ... The sNDA was submitted to support full approval of OCA for this indication based on data from the COBALT trial ...

On Monday, the FDA said the company could continue testing its combination COVID-19-flu and standalone flu vaccines. Novavax (NVAX) shares dropped Tuesday morning after the company slashed its ...